Table 2 Cytotoxicity and antiviral activity of mixtures obtained through the modified prebiotic conditions.
From: Harnessing prebiotic formamide chemistry: a novel platform for antiviral exploration
Cmpd. | CC50a (Huh7) | IC50 b WNV | IC50 DENV | CC50 (H9) | IC50 HIV |
|---|---|---|---|---|---|
Mix 1a | 40 | NAc | NA | 40 | NA |
Mix 1b | 12 | 4.8 ± 3.8 (SId = 2.5) | 1.9 ± 0.4 (SI = 9.4) | 18 | NA |
Mix 1c | 64 | 3.3 ± 1.4 (SI = 19.5) | 7.2 ± 2.7 (SI = 8.8) | 26 | NA |
Mix 1d | 20 | NA | NA | 24 | NA |
Mix 2a | > 80 | NA | NA | > 40 | NA |
Mix2b | > 80 | NA | NA | > 40 | NA |
Mix 2c | 56 | NA | NA | 40 | 6.2 ± 1.9 (SI = 6.4) |
Mix 2d | > 80 | NA | NA | > 40 | NA |
Mix 3a | 24 | 8.0 ± 2.9 (SI = 3) | 4.3 ± 1.9 (SI = 5.6) | 18 | NA |
Mix 3b | > 80 | 4.3 ± 3.3 (SI > 18.7) | NA | 48 | NA |
Mix 3c | > 80 | 3.2 ± 0.2 (SI > 25.3) | 13.6 ± 2.7 (SI > 7.1) | 40 | NA |
Mix 3d | 72 | NA | NA | 40 | NA |
